|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
5
|
|
pubmed:dateCreated |
2000-12-8
|
|
pubmed:abstractText |
The most effective option for the medical treatment of patients with acromegaly is the use of somatostatin analogues. Long-acting depot formulations for intramuscular injection of two somatostatin analogues have recently become available: octreotide acetate LAR (Sandostatin LAR, Novartis Pharma AG) and lanreotide SR (Somatuline, Ipsen Biotech). We wished to compare efficacy of octreotide LAR and lanreotide SR in acromegalic patients.
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Nov
|
|
pubmed:issn |
0300-0664
|
|
pubmed:author |
pubmed-author:AjzenbergCC,
pubmed-author:BachelotYY,
pubmed-author:BenitoPP,
pubmed-author:BoerlinVV,
pubmed-author:BringerJJ,
pubmed-author:CarolRR,
pubmed-author:ChansonPP,
pubmed-author:CharbonnelBB,
pubmed-author:CortenII,
pubmed-author:DelemerBB,
pubmed-author:Escobar-JiménezFF,
pubmed-author:FoubertLL,
pubmed-author:GaztambideSS,
pubmed-author:JockenhoevelFF,
pubmed-author:KuhnJ MJM,
pubmed-author:LeclereJJ,
pubmed-author:LorcyYY,
pubmed-author:PerlemuterLL,
pubmed-author:PresteleHH,
pubmed-author:RogerPP,
pubmed-author:RohmerVV,
pubmed-author:SantenRR,
pubmed-author:SassolasGG,
pubmed-author:ScherbaumW AWA,
pubmed-author:SchopohlJJ,
pubmed-author:TorresEE,
pubmed-author:VarelaCC,
pubmed-author:VillamilFF,
pubmed-author:WebbS MSM
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
53
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
577-86
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:11106918-Acromegaly,
pubmed-meshheading:11106918-Adolescent,
pubmed-meshheading:11106918-Adult,
pubmed-meshheading:11106918-Aged,
pubmed-meshheading:11106918-Delayed-Action Preparations,
pubmed-meshheading:11106918-Drug Administration Schedule,
pubmed-meshheading:11106918-Female,
pubmed-meshheading:11106918-Hormones,
pubmed-meshheading:11106918-Human Growth Hormone,
pubmed-meshheading:11106918-Humans,
pubmed-meshheading:11106918-Insulin-Like Growth Factor I,
pubmed-meshheading:11106918-Male,
pubmed-meshheading:11106918-Middle Aged,
pubmed-meshheading:11106918-Octreotide,
pubmed-meshheading:11106918-Peptides, Cyclic,
pubmed-meshheading:11106918-Pituitary Irradiation,
pubmed-meshheading:11106918-Random Allocation,
pubmed-meshheading:11106918-Somatostatin,
pubmed-meshheading:11106918-Treatment Outcome
|
|
pubmed:year |
2000
|
|
pubmed:articleTitle |
Comparison of octreotide acetate LAR and lanreotide SR in patients with acromegaly.
|
|
pubmed:affiliation |
Novartis Pharma AG, Clinical Research and Development, Basel, Switzerland.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Comparative Study,
Randomized Controlled Trial,
Controlled Clinical Trial,
Research Support, Non-U.S. Gov't,
Multicenter Study
|
